Analysts are intrested in these 5 stocks: ( (ARI) ), ( (EXEL) ), ( (DVN) ), ( (QCOM) ) and ( (OKLO) ). Here is a breakdown of their recent ratings and the rationale behind them.
Analysts are taking a cautious stance on Apollo Commercial Real Estate Finance as the company moves into liquidation. Tom Catherwood now rates ARI at Hold, noting that while management’s plan to return cash to shareholders is welcome, expected book value erosion of roughly $0.98 per share from frictional costs and asset sales leaves the stock looking fairly valued.
Investors should watch how quickly Apollo sells its remaining five properties, including The Brook in Brooklyn and hotels in Washington, D.C. and Atlanta. The timing and pricing of these deals will dictate the ultimate payout, and with shares already at about 0.90x book value and a 6% yield, the call from the Street is to collect near‑term dividends but avoid betting on outsized upside.
Biotech name Exelixis is also drawing a Hold stance as its flagship cancer drug Cabometyx approaches a key patent cliff. Gregory Renza has assumed coverage and kept EXEL at Hold with a $54 target, arguing that while Cabometyx remains a cash‑generating leader in kidney cancer and neuroendocrine tumors, its 2031 loss of exclusivity caps the runway and raises the bar for the next growth driver.
The firm’s next‑gen drug zanzalintinib could be that driver, with a December 3 PDUFA date in colorectal cancer and multiple solid‑tumor trials that together form a “pipeline‑in‑a‑product” narrative. Yet mixed data signals and early‑stage ADC programs mean the story is still a “show‑me” one, and despite strong buybacks and a solid cash pile, the analyst prefers to wait for clearer momentum before getting more bullish.
Energy investors are seeing a brighter picture at Devon Energy following its merger with Coterra. Neil Mehta reinstated coverage with a Buy rating and a $54 price target, highlighting that DVN now trades at about a 15% free cash flow yield on 2027‑2028 estimates, well above the roughly 11% average of large‑cap peers like OXY, COP, FANG and EOG.
The pro forma company is focused on optimizing its Delaware Basin assets and targeting $1 billion in annual merger synergies by year‑end 2027, while an updated capital‑return framework aims to send up to 70% of free cash flow back to investors. After notable underperformance versus peers and the energy ETF, the analyst sees room for mean reversion as synergy progress, portfolio moves and operational efficiencies catalyze a re‑rating.
In semiconductors, Qualcomm is being pulled into the AI spotlight as management lays out surprisingly bold data‑center revenue goals. Joseph Moore has upgraded QCOM to Hold (equal weight) after the company guided to $5 billion in AI‑related data‑center sales for FY27, a figure at least twice what many expected and enough to place Qualcomm among emerging beneficiaries of the trillion‑dollar AI infrastructure market.
Longer‑term guidance of $15 billion by FY29 is viewed as more aspirational, and Moore still sees Qualcomm as a late entrant versus incumbents like NVIDIA and newer players such as Cerebras. With AI accelerators and processors facing stiff competition and lingering smartphone headwinds, he prefers not to call it a top‑pick yet, but the credible near‑term revenue narrative makes it hard to forecast underperformance.
Finally, advanced nuclear start‑up Oklo is attracting attention but not yet conviction from Wall Street. Joseph Osha has initiated coverage of OKLO with a Neutral rating, signaling interest in the company’s micro‑reactor concept but also acknowledging that it remains an early‑stage story without meaningful revenue guidance or detailed financial forecasts.
For investors intrigued by the future of clean baseload power, Oklo represents a speculative bet that could benefit from policy support and growing demand for reliable low‑carbon energy. Still, with commercial timelines and economics yet to be proven, the current analyst view is to watch the name from the sidelines rather than commit fresh capital at this stage.


